Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ cell content

@article{Weaver1997EngraftmentAO,
  title={Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ cell content},
  author={Ch. Weaver and J L Potz and J. J. Redmond and K M Tauer and L Schwartzberg and Paul Kaywin and Robert Drapkin and Barbara L Grant and P P Unger and Christopher Allen and K Longin and B G Zhen and Bill Hazelton and C A Buckner},
  journal={Bone Marrow Transplantation},
  year={1997},
  volume={19},
  pages={1103-1110}
}
Engraftment kinetics after high-dose chemotherapy (HDC) were evaluated in patients receiving autologous peripheral blood stem cell (PBSC) infusions with a low CD34+ cell content. Forty-eight patients were infused with <2.5 × 106 CD34+ cells/kg; 36 because of poor harvests and 12 because they electively received only a fraction of their harvested cells. A median of 2.12 × 106 CD34+ cells/kg (range, 1.17–2.48) were infused following one of seven different HDC regimens. All patients achieved… CONTINUE READING